Enhancement of chemotherapy agents.
The interaction in vivo between misonidazole and cytotoxic drugs is reviewed. In general MISO interacts best with bifunctional alkylating agents and nitrosoureas when there is generally a therapeutic gain at large MISO doses. The interaction is unlikely to be a result of pharmacokinetic effects of MISO, but may reflect its ability to inhibit recovery from drug induced damage. It is important to extend these studies to clinically relevant MISO doses simulating human pharmacokinetics.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D051379:Mice; D008920:Misonidazole / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D008920:Misonidazole